Fisher Scientific International Inc

Fisher Scientific International — Merrill Lynch Global Pharmaceutical, Biotech and Medical Device Conference 2004

26 slides from Fisher Scientific International's conference presentation, Feb 5, 2004

  1. Slide 1: The World Leader in Serving Science

    Slide 1: The World Leader in Serving Science

    The World Leader in Serving Science Merrill Lynch Global Pharmaceutical, Biotech and Medical Device Conference February 5, 2004

  2. Slide 2: Safe Harbor and Regulation G Statement

    Slide 2: Safe Harbor and Regulation G Statement

    The Securities and Exchange Commission encourages companies to disclose forward- looking information so that investors can better understand a company's future prospects and make informed investment decisions. This presentation contains these types of statements, which are "forward-looking statement

  3. Slide 3: Fisher at a Glance

    Slide 3: Fisher at a Glance

    Fisher at a Glance - Founded in 1902 Proprietary 4 5% Distributed 55% * Midpoint of management estimates 350,000 customers Global scientific research $20 U.S. clinical laboratory $10 2004E sales: $4.0 Bils* Growing Markets ($ Bils) Favorable market dynamics Broad Product Portfolio One stop shop Dive

  4. Slide 4: Diverse Customer Base

    Slide 4: Diverse Customer Base

    7 Scientific Research 77% Clinical Lab 23% No Customer > 2.5% of Sales Diverse Customer Base Pharma 0.26 Hospitals 0.16 Reference Labs 0.07 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12

  5. Slide 5: Market Dynamics Are Favorable

    Slide 5: Market Dynamics Are Favorable

    Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 R&D spending steadily increasing Market Dynamics Are Favorable Customer Base 9 Pharma/Biotech 26% Colleges & Universities 12% Medical Research 7% Other Scientific Research 32%

  6. Slide 6: Market Dynamics Are Favorable

    Slide 6: Market Dynamics Are Favorable

    Pressure on drug development costs R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Pharma/Biotech 26% 11

  7. Slide 7: Market Dynamics Are Favorable

    Slide 7: Market Dynamics Are Favorable

    Pressure on drug development costs Aging population R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Pharma/Biotech 26% Colleges & Universities 12% Medical Research 7% Hospitals and

  8. Slide 8: Market Dynamics Are Favorable

    Slide 8: Market Dynamics Are Favorable

    Pressure on drug development costs Aging population R&D spending steadily increasing Growth in homeland security spending Market Dynamics Are Favorable Customer Base 15 Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Hospitals and Reference Labs 23% Other S

  9. Slide 9: U.S. Scientific Research Market Overview

    Slide 9: U.S. Scientific Research Market Overview

    Sources: Laboratory Products Association, SDI Inc., SAI and management estimates. $10 billion Growth Rate: 5 - 8% Scientific Research Market U.S. Market Overview U.S. R&D Spending CAGR: 9% Other 0.71 E-Merck 0.13 Fisher (including Columbia) 0.16 1960 1965 1970 1975 1980 1985 1990 1995 2003 (Excl. De

  10. Slide 10: U.S. Clinical Laboratory Market Overview

    Slide 10: U.S. Clinical Laboratory Market Overview

    Sources: The Freedonia Group and management estimates. U.S. Market Overview $9.5 billion Growth Rate: 4 - 5% Number of IVD Tests (Test Per Person) 3.3 3.8 4.5 5.4 6.5 IVD Tests (in Bils) 1989 1993 1998 2003 2008 East 13.3 14.5 16.5 19.1 22 Clinical Laboratory Market Other 0.85 Cardinal 0.08 Fisher (

  11. Slide 11: Company Capabilities

    Slide 11: Company Capabilities

    The Fisher brand Global logistics Industry-leading sales force Company Capabilities

  12. Slide 12: The Fisher Brand

    Slide 12: The Fisher Brand

    100 years of serving science Broad proprietary product and service portfolio Global brand recognition Company Capabilities The Fisher Brand

  13. Slide 13: Global Logistics Capabilities

    Slide 13: Global Logistics Capabilities

    Global Logistics Capabilities Company Capabilities 30,000 shipments daily 40 distribution facilities E-commerce systems

  14. Slide 14: Industry-Leading Sales Force

    Slide 14: Industry-Leading Sales Force

    1,500 sales reps 1,200 customer service reps Industry-Leading Sales Force Company Capabilities Supply chain solutions 300 life science, chemical and technical specialists End-user sales and support

  15. Slide 15: Reduced Investment in Working Capital

    Slide 15: Reduced Investment in Working Capital

    1997 1998 1999 2000 2001 2002 2003 East 0.155 0.131 0.112 0.093 0.091 0.086 0.077 * Excludes impact of Perbio acquisition. Note: Working capital is defined as the average balance of the last four quarters of receivables plus inventories less accounts payable. Company Capabilities Reduced Investment

  16. Slide 16: Margin Enhancement Strategy

    Slide 16: Margin Enhancement Strategy

    Proprietary (45% of sales) - Self-manufactured - Private labeled - Exclusives Distributed (55% of sales) Gross Margin % Margin Enhancement Strategy 31

  17. Slide 17: Acquisitions Drive Margin Enhancement

    Slide 17: Acquisitions Drive Margin Enhancement

    16 Acquisitions Drive Margin Enhancement Diagnostic Reagents Biochemicals Acros Maybridge Mimotopes Pierce HyClone Clinical Trial Services Margin Enhancement Strategy 33

  18. Slide 18: Margin Enhancement Strategy

    Slide 18: Margin Enhancement Strategy

    35 Margin Enhancement Strategy Fisherbrand Powerful Channel Position Leading Products in Key Markets Drug Discovery Drug Development Healthcare Delivery Research and Development Fisher Chemicals

  19. Slide 19: Significant Margin Expansion

    Slide 19: Significant Margin Expansion

    1997 1998 1999 2000 2001 2002 2003 2004F* East 0.054 0.063 0.069 0.068 0.073 0.075 0.078 0.087 * Midpoint of management estimates. Note: Operating income as a percentage of sales - excludes restructuring and non-recurring expenses. Margin Enhancement Strategy Significant Margin Expansion 330 bps 37

  20. Slide 20: Financial Highlights

    Slide 20: Financial Highlights

    Financial Highlights

  21. Slide 21: Sales Growth

    Slide 21: Sales Growth

    Sales Growth ($ in billions) 1997 1998 1999 2000 2001 2002 2003 2004F* *Midpoint of management estimates - excludes the impact of foreign exchange rate changes. CAGR: 8%

  22. Slide 22: Earnings Per Share Growth

    Slide 22: Earnings Per Share Growth

    Earnings Per Share Growth 1997 1998 1999 2000 2001 2002 2003 2004F* *Midpoint of management estimates Note: Excludes restructuring and non-recurring expenses. CAGR: 27%

  23. Slide 23: Strong Cash Flow

    Slide 23: Strong Cash Flow

    Strong Cash Flow (1) Midpoint of management estimates. (2) Defined as cash flow from operations less capital expenditures divided by diluted shares outstanding. (3) Defined as free cash flow per share divided by closing share price on 12/31/03 and 2/02/04 for 2003 and 2004 respectively. (1) (2) (3)

  24. Slide 24: Increasing Return on Committed Capital

    Slide 24: Increasing Return on Committed Capital

    1997 1998 1999 2000 2001 2002 2003 East 0.2 0.3 0.33 0.36 0.39 0.413 0.43 Note: Return on committed capital is defined as adjusted operating income excluding intangible amortization as a percentage of committed capital (property, plant and equipment plus accounts receivable plus inventories less acc

  25. Slide 25: Investment Highlights

    Slide 25: Investment Highlights

    Investment Highlights Strong earnings and cash flow growth Favorable market dynamics Significant margin enhancement opportunities Strong management team

  26. Slide 26: The World Leader in Serving Science

    Slide 26: The World Leader in Serving Science

    The World Leader in Serving Science

Source: SEC EDGAR · 8-K filed Feb 5, 2004

More decks from Fisher Scientific International Inc